CHRONIC
DISEASE AND PHYSICAL ACTIVITY
OSTEOARTHRITIS
TREATMENT TO
ATHLETES
– A REVIEW OF THE RECENT LITERATURE
REGARDING THE SLOW ACTING DRUGS
A. Murgu, A.
Ionescu, C. Ciocan, M. Baroga
University
of Medicine “Carol Davila” Bucharest, National
Institute of Sports Medicine, Romania
BACKGROUND. Osteoarthritis is a
major social and medical problem by its incidence and consequent
functional deficit. Incidence of the disease varies from 7% to men and
2% to women of 18-24 years of age to 100% to old people in their
80’s.
METHODS. A review of the last ten years
specific literature shows the latest news regarding the role and action
of the nutraceuticals (glucosaminoglicans and condroitinsulphate) as a
part of the therapeutic EULAR protocol of osteoarthritis. A
meta-analysis made by JAMA in 2000 evaluates the studies published
between 1966 an 1999 selected only 15 studies rigorously written.
RESULTS.
The studies presented are a strong evidence for the therapeutical
eficacity, well defined joint protection role and very low side effects
of the dietary supplements mentioned above.
CONCLUSION.
Glucosaminoglicans and condroitinsulphate are safe and officially
included in the therapeutical protocole for osteoarthritis
| 
